OCUGEN INC

OCGNNASDAQ

🏆 #2514 by market capEarnings Nov 4US Equity

$1.37▲ $0.06 (+4.58%)

Market closed · at close

1h—

24h▲ 4.6%

7d—

14d—

30d—

1y—

🏦Market Cap

$464M

Small Cap

📈Revenue Growth (YoY)

+0.4%

Slowing

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

92.0x

Expensive

Otter Score

Weak

No chart data available for OCGN.

Trading Snapshot

Day Range: $1.36 – $1.38
52-Week Range: $0.96 – $2.73
Volume: $2.12B
Avg Volume: $1.92B
Shares Outstanding: 338.5M
Next Earnings: Oct 19, 2026

Fundamentals Snapshot

Annual Revenue: $4M
Last Q Revenue: $1M
P/E Ratio: —
P/S Ratio: 92.0x
EPS (TTM): $-0.20
Dividend Yield: —

Why Investors Own OCGN

✓High-growth profile — revenue up +22.0% YoY with expanding US Equity exposure.
✓Healthy economics — 46% gross margin and 18% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$4M▲ +24.5% YoY

Gross Margin (TTM)

46.3%▲ +1.9% YoY

Operating Income (TTM)

$661,950▲ +24.5% YoY

Free Cash Flow (TTM)

$803,166▲ +24.5% YoY

About OCUGEN INC

Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic conditions leading to blindness. The company's developmental pipeline features several key candidates: OCU400: An innovative gene therapy designed to reinstate both the function and structural integrity of the retina across a broad spectrum of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and Leber congenital amaurosis. OCU410: Another gene therapy candidate, currently being developed to address dry age-related macular degeneration (AMD). OCU200: A novel fusion protein, presently undergoing preclinical evaluation for its potential in treating diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen maintains significant strategic collaborations, including a partnership with CanSino Biologics Inc. for the joint development and manufacturing of gene therapies, and an alliance with Bharat Biotech for the commercialization of COVAXIN within the United States market. The company's corporate headquarters are situated in Malvern, Pennsylvania.

🦦